An Open-Label Exploratory Study of Fosigotifator in Participants With Vanishing White Matter Disease

October 16, 2026 updated by: Calico Life Sciences LLC

A Phase 1b/2 Open-label Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy Following Fosigotifator Administration in Adult and Pediatric Subjects With Vanishing White Matter Disease

Fosigotifator is an investigational drug being researched for the treatment of Vanishing White Matter disease in adult, pediatric and infant participants. This is a 201-week, open-label, multiple cohort study enrolling adults, pediatric and infant participants with Vanishing White Matter disease.

Participants will attend regular visits during the course of the study and complete medical assessments, blood tests, questionnaires, and be evaluated for side effects.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

50

Phase

  • Phase 2
  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Quebec
      • Montreal, Quebec, Canada, H3H2L9
        • Recruiting
        • McGill University Health Centre - Glen Site
    • North Holland
      • Amsterdam, North Holland, Netherlands, 1081 HV
        • Recruiting
        • Amsterdam UMC, locatie VUmc /ID# 270955
    • Massachusetts
      • Boston, Massachusetts, United States, 02114
        • Recruiting
        • Massachusetts General Hospital /ID# 270960
    • Pennsylvania
      • Philadelphia, Pennsylvania, United States, 19104
        • Recruiting
        • Children's Hospital of Philadelphia
    • Utah
      • Salt Lake City, Utah, United States, 84112-5339
        • Recruiting
        • University of Utah /ID# 255624

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

6 months and older (Child, Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Males and females ≥18 y of age (Cohort 1 and Cohort 1b - adults), ≥12 y and <18 y of age (Cohort 2 - adolescents), ≥6 y and <12 y of age (Cohort 3 - children), and ≥6 mos and <6 y of age (Cohort 4 - children [≥1 y and <6 y of age] and infants [≥6 mos and <1 y of age]) at the time of Screening.

  2. Subject must have VWM disease defined as:

    • A clinical diagnosis by a physician experienced in the assessment of VWM disease, AND
    • A molecular diagnosis of VWM disease (Note: Subjects who can provide a verified laboratory report of previously performed VWM molecular diagnosis, including the specific mutation(s), will not be required to reconfirm diagnosis before Screening), AND
    • A magnetic resonance imaging (MRI) presentation consistent with VWM disease, as assessed by a neuroradiologist or by a physician experienced in the assessment of VWM disease except for presymptomatic homozygous carriers of Cree leukoencephalopathy (EIF2B5 R195H) or other mutation with known imminent risk of significant clinical decline or death (requires approval from Sponsor).
  3. Subject must have a designated caregiver who is able to complete the respective caregiver ce ntered assessments. The caregiver must be consistently present at visits, including telehealth visits, to report on symptoms and comply with the protocol. The caregiver must be willing to provide informed consent.

  4. Subject is willing and able to give informed consent. Where local regulations permit inclusion of participants deemed not able to provide informed consent, a legally authorized representative (LAR) must provide informed consent on the subject's behalf, and the subject must provide assent, in accordance with the local regulations, guidelines, and Institutional Review Board (IRB), or Independent Ethics Committee (IEC). If the subject becomes cognitively impaired (diminished capacities) during the study and is unable to provide informed consent, the subject should be discontinued from the study unless local regulations permit inclusion of participants deemed not able to provide informed consent. In such case, a LAR must provide informed consent on behalf of the subject and the subject must provide assent as per local regulations, guidelines, and IRB or IEC. Careful consideration will be given to ensure that cognitive impairment/diminished capacity does not limit the subject's right to withdraw from the study. The LAR and the caregiver can be the same person.

  5. Subjects in Cohorts 1, 1b, 2, and 3 must meet criteria a and at least 1 of the other criteria listed below (b or c):

    • Medical history of at least 1 neurological symptom that is assessed by the investigator as having a reasonable possibility of being related to VWM disease
    • Motor criteria as defined below:

    All age groups:

    Inability to walk 10 or more steps with or without light support of 2 hands

    - Cognitive criteria as defined below (Note: Subjects are not required to complete testing if they meet the motor criteria or if they are able to provide source documentation of prior cognitive testing performed by a qualified psychologist and meeting eligibility criteria obtained in the past 12 months):

    Adults and adolescents ≥16 y of age must have:

    A perceptual reasoning index <50 (Wechsler Adult Intelligence Scale, fourth edition [WAIS-IV])

    Adolescents and children ≥6 y and <16 y of age must have:

    A visuospatial reasoning index <50 (block design, visual puzzles, Wechsler Intelligence Scale for Children performance, fifth edition [WISC-V]) AND A fluid reasoning index <50 (matrix reasoning, figure weights, WISC-V). Note: At the Sponsor's discretion, pediatric subjects <16 y of age who are unable to complete the subtests for calculating BOTH indices of the WISC-V due to functional impairment (e.g., due to fine motor or visual impairment) may meet inclusion criteria by a score <50 on either the visuospatial reasoning index OR the fluid reasoning index of the WISC-V.

    Pediatric subjects in Cohort 4 must meet both criteria a and b below, or criterion c:

    Medical history of at least 1 neurological symptom that is assessed by the investigator as having a reasonable possibility of being related to VWM disease

    Motor criteria as defined below:

    More than minimal head control as demonstrated by:

    While in prone position, the subject can lift his/her head and sustain the position for 10 seconds and bring his/her arms actively to weight bearing in that position Presymptomatic and homozygous for Cree Leukoencephalopathy (EIF2B5 R195H) or other mutation with known imminent risk of significant clinical decline or death (sponsor must be notified and provide approval prior to screening and enrolling a patient that meets eligibility with only this criterion).

  6. All male subjects who are sexually active and not surgically sterilized must agree to use an acceptable contraceptive method. Additionally, male subjects must agree to not donate sperm during the study and until 30 days after the final dose of study drug.

  7. All female subjects who are sexually active and of childbearing potential must agree to use an acceptable contraceptive method. Additionally, female subjects must agree to not donate eggs during the study and for 30 days after the final dose of study drug.

  8. Canada-specific Cohort 5: Male and female infant subjects between 0 mos and <6 mos of age at the time of Screening.

  9. Canada-specific Cohort 5: Subject body weight ≥5 kg at the time of the Baseline visit. The screening period can be extended by up to 30 days to ensure that this minimum weight is met at the Baseline visit.

  10. Canada-specific Cohort 5: Homozygous carriers of Cree leukoencephalopathy (EIF2B5 R195H) or other mutation(s) with known imminent risk of significant clinical decline or death (the Sponsor must be notified and provide approval prior to screening and enrolling a patient that meets eligibility with only this criterion).

An MRI presentation consistent with VWM disease is not required for Cohort 5. Exclusion Criteria

  1. Pediatric subjects ≥6 mos and <6 y of age must not be on any form of respiratory support at the time of Screening.
  2. Subject who has any clinically significant electrocardiogram (ECG) abnormalities, including QT interval corrected for heart rate using Fridericia's correction formula (QTcF) of >450 msec for adult males, >470 msec for adult females, or >450 msec for adolescents ≥12 y and <18 y of age (Cohort 2) and children ≥6 y and <12 y of age (Cohort 3), or >414 msec for infants and children ≥0.5 y and <6 y of age (Cohort 4).
  3. Subject with current or history of abnormal screening laboratory or imaging results that, in the opinion of the Investigator, are indicative of any significant cardiac, endocrinologic, hematologic, hepatic, immunologic, infectious, metabolic, urologic, pulmonary, gastrointestinal, dermatologic, psychiatric, renal, neurologic, and/or other major disease (other than VWM) that would preclude administration of FGT or safe participation in the study Abnormal adrenal function, defined as confirmed abnormal random cortisol or ACTH at Screening (see Section 7.2.8 for cortisol and ACTH thresholds) Participants may undergo repeat cortisol and ACTH testing once, in order to establish normal adrenal function. If repeat cortisol and/or ACTH testing is abnormal, at the Investigator's discretion, the participant may undergo cosyntropin stimulation testing to establish normal adrenal function to meet eligibility criteria.
  4. Subject who has suicidal ideation at the Screening Visit (V1). Prior medical history and/or Columbia-Suicide Severity Rating Scale (C-SSRS) may be used to inform the Investigator's decision.
  5. Changes in medication use for the management of VWM disease symptoms within the 4 weeks preceding Screening.
  6. Seizure disorder not considered adequately controlled by the Investigator within the 6 months preceding Screening.
  7. Subject who, in the opinion of the Investigator, is incapable of completing study-required visits and procedures to assess primary and secondary endpoints (e.g., due to severe comorbid conditions or severity of VWM disease).
  8. Subjects who are pregnant, breastfeeding, or providing breast milk. Note: Infant subjects are permitted to receive breast milk from a non-participant mother or caregiver (who is not receiving the study intervention).
  9. Canada-specific Cohort 5: Subjects between 0 mos and <6 mos of age must not be on any form of respiratory support at the time of Screening.
  10. Canada-specific Cohort 5: Subject who has any clinically significant ECG abnormalities, including QT interval corrected for heart rate using Fridericia's correction formula (QTcF) of >414 msec for infants between 0 mos and <6 mos of age

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Fosigotifator - Cohort 1

Cohort 1: VWM adults >= 18 years.

Oral Use

Other Names:
  • ABBV-CLS-7262
Experimental: Fosigotifator - Cohort 1b

Cohort 1b: VWM adults >= 18 years.

Oral Use

Other Names:
  • ABBV-CLS-7262
Experimental: Fosigotifator - Cohort 2

Cohort 2: VWM children>= 12 y and <18 years.

Oral Use

Other Names:
  • ABBV-CLS-7262
Experimental: Fosigotifator - Cohort 3

Cohort 3: VWM children >= 6 y and <12 years.

Oral Use

Other Names:
  • ABBV-CLS-7262
Experimental: Fosigotifator - Cohort 4

Cohort 4: VWM children >= 6 months and <6 years.

Oral Use

Other Names:
  • ABBV-CLS-7262
Experimental: Fosigotifator - Cohort 5 (Canada Only)

VWM Children >0 and <6 months

Oral Use

Other Names:
  • ABBV-CLS-7262

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Incidence of Treatment-Emergent Adverse Events
Time Frame: Baseline up to Approximately Day 28

Number of participants with treatment-related adverse events as assessed by CTCAE v4.03

Baseline up to Approximately Day 28
Number of Participants with Change in Vital Signs
Time Frame: Baseline up to Approximately Day 28

Number of Participants with Change in Vital Signs will be assessed.

Baseline up to Approximately Day 28
Number of Participants with Change in ECG
Time Frame: Baseline up to Approximately Day 28

Number of Participants with Change in ECG will be assessed.

Baseline up to Approximately Day 28
Number of Participants with Change in Clinical Laboratory Tests
Time Frame: Baseline up to Approximately Day 28

Number of participants with change in clinical laboratory tests will be assessed.

Baseline up to Approximately Day 28
Change from Baseline in Columbia-Suicide Severity Rating Scale (C-SSRS)
Time Frame: Baseline up to Approximately Day 28

The C-SSRS is a systematically administered instrument that reports the severity of both suicidal ideation and behavior, with a higher score denoting more severe suicidal ideation and behavior.

Baseline up to Approximately Day 28
Plasma Concentration of Fosigotifator
Time Frame: Baseline up to approximately Week 96

Maximum Plasma Concentration [Cmax]

Baseline up to approximately Week 96
Time to Cmax (Tmax) of Fosigotifator
Time Frame: Baseline up to approximately Week 96

Tmax of Fosigotifator

Baseline up to approximately Week 96
Area Under the Plasma Concentration-Time Curve (AUC0-24h) of Fosigotifator
Time Frame: Baseline up to approximately Week 96

AUC0-24h of Fosigotifator

Baseline up to approximately Week 96
Trough Concentration (Ctrough) of Fosigotifator
Time Frame: Baseline up to approximately Week 96

Ctrough of Fosigotifator

Baseline up to approximately Week 96
Terminal Elimination Half-Life (t1/2) of Fosigotifator
Time Frame: Baseline up to approximately Week 96

t1/2 of Fosigotifator

Baseline up to approximately Week 96

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Incidence of Treatment-Emergent Adverse Events
Time Frame: Baseline up to Approximately Week 197

Number of patients with treatment-related adverse events as assessed by CTCAE v4.03

Baseline up to Approximately Week 197
Number of Participants with Change in Vital Signs
Time Frame: Baseline up to approximately Week 197

Number of Participants with Change in Vital Signs will be assessed.

Baseline up to approximately Week 197
Number of Participants with Change in ECG
Time Frame: Baseline up to approximately Week 197

Number of Participants with Change in ECG will be assessed.

Baseline up to approximately Week 197
Number of Participants with Change in Clinical Laboratory Tests
Time Frame: Baseline up to approximately Week 197

Number of participants with change in clinical laboratory tests will be assessed.

Baseline up to approximately Week 197
Change from Baseline in Columbia-Suicide Severity Rating Scale (C-SSRS)
Time Frame: Baseline up to approximately Week 197

The C-SSRS is a systematically administered instrument that reports the severity of both suicidal ideation and behavior, with a higher score denoting more severe suicidal ideation and behavior.

Baseline up to approximately Week 197
Number of Participants with Change in Magnetic Resonance Imaging (MRI)
Time Frame: Baseline up to approximately Week 192

Change in Brain Magnetic Resonance Imaging (MRI) associated with adverse events.

Baseline up to approximately Week 192

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 13, 2023

Primary Completion (Estimated)

November 1, 2027

Study Completion (Estimated)

October 1, 2035

Study Registration Dates

First Submitted

February 23, 2023

First Submitted That Met QC Criteria

March 3, 2023

First Posted (Actual)

March 7, 2023

Study Record Updates

Last Update Posted (Actual)

October 19, 2026

Last Update Submitted That Met QC Criteria

October 16, 2026

Last Verified

October 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • M23-523
  • 2023-505704-30-00 (Other Identifier: EU CT)
  • 2023 (U.S. NIH Grant/Contract)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

Yes

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.